Investigation of Soluble and Transmembrane CTLA-4 Isoforms in Serum and Microvesicles

Expression of the CTLA-4 gene is absolutely required for immune homeostasis, but aspects of its molecular nature remain undefined. In particular, the characterization of the soluble CTLA-4 (sCTLA-4) protein isoform generated by an alternatively spliced mRNA of CTLA4 lacking transmembrane-encoding exon 3 has been hindered by the difficulty in distinguishing it from the transmembrane isoform of CTLA-4, Tm-CTLA-4. In the current study, sCTLA-4 has been analyzed using novel mAbs and polyclonal Abs specific for its unique C-terminal amino acid sequence. We demonstrate that the sCTLA-4 protein is secreted at low levels following the activation of primary human CD4+ T cells and is increased only rarely in the serum of autoimmune patients. Unexpectedly, during our studies aimed to define the kinetics of sCTLA-4 produced by activated human CD4+ T cells, we discovered that Tm-CTLA-4 is associated with microvesicles produced by the activated cells. The functional roles of sCTLA-4 and microvesicle-associated Tm-CTLA-4 warrant further investigation, especially as they relate to the multiple mechanisms of action described for the more commonly studied cell-associated Tm-CTLA-4.

[1]  David L. Stokes,et al.  Polarized release of TCR-enriched microvesicles at the T cell immunological synapse , 2014, Nature.

[2]  A. Kaneko,et al.  Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients , 2013, Modern rheumatology.

[3]  R. Rodríguez,et al.  Kinetics of the CTLA-4 isoforms expression after T-lymphocyte activation and role of the promoter polymorphisms on CTLA-4 gene transcription. , 2013, Human immunology.

[4]  J. Lötvall,et al.  Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes , 2013, Journal of extracellular vesicles.

[5]  E. Telemo,et al.  Activated Human T Cells Secrete Exosomes That Participate in IL-2 Mediated Immune Response Signaling , 2012, PloS one.

[6]  Darrell M. Wilson,et al.  Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial , 2011, The Lancet.

[7]  H. Leffers,et al.  Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry , 2011, Annals of the rheumatic diseases.

[8]  B. Xia,et al.  Association of cytotoxic T lymphocyte associated antigen‐4 gene (rs60872763) polymorphism with Crohn's disease and high levels of serum sCTLA‐4 in Crohn's disease , 2011, Journal of gastroenterology and hepatology.

[9]  Fátima Sánchez-Cabo,et al.  Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells , 2011, Nature communications.

[10]  J. Xiang,et al.  Dendritic Cells Recruit T Cell Exosomes via Exosomal LFA-1 Leading to Inhibition of CD8+ CTL Responses through Downregulation of Peptide/MHC Class I and Fas Ligand-Mediated Cytotoxicity , 2010, The Journal of Immunology.

[11]  Jing Cui,et al.  Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci , 2010, Nature Genetics.

[12]  M. Tector,et al.  Biochemical analysis of CTLA-4 immunoreactive material from human blood , 2009, BMC Immunology.

[13]  L. Greco,et al.  A functional soluble form of CTLA-4 is present in the serum of celiac patients and correlates with mucosal injury. , 2009, International immunology.

[14]  M. Deschamps,et al.  Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity , 2009, Arthritis research & therapy.

[15]  J. Yates,et al.  Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT). , 2009, Journal of proteome research.

[16]  Cisca Wijmenga,et al.  Shared and distinct genetic variants in type 1 diabetes and celiac disease. , 2008, The New England journal of medicine.

[17]  M. Tector,et al.  Lack of association between sCTLA-4 levels in human plasma and common CTLA-4 polymorphisms , 2008, Journal of Negative Results in BioMedicine.

[18]  T. Nomura,et al.  CTLA-4 Control over Foxp3+ Regulatory T Cell Function , 2008, Science.

[19]  A. Martini,et al.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial , 2008, The Lancet.

[20]  Shimon Sakaguchi,et al.  Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation , 2008, Proceedings of the National Academy of Sciences.

[21]  H. Genant,et al.  Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial , 2007, Annals of the rheumatic diseases.

[22]  Riitta Lahesmaa,et al.  Exosomes with Immune Modulatory Features Are Present in Human Breast Milk1 , 2007, The Journal of Immunology.

[23]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[24]  Loise M. Francisco,et al.  Blockade of CTLA-4 on CD4+CD25+ Regulatory T Cells Abrogates Their Function In Vivo1 , 2006, The Journal of Immunology.

[25]  C. Cilio,et al.  Cytotoxic T lymphocyte antigen‐4‐dependent down‐modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T‐cell‐mediated suppression , 2006, Immunology.

[26]  Mark M Davis,et al.  T cells use two directionally distinct pathways for cytokine secretion , 2006, Nature Immunology.

[27]  Aled Clayton,et al.  Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids , 2006, Current protocols in cell biology.

[28]  V. Dharnidharka.  Costimulation blockade with belatacept in renal transplantation. , 2005, The New England journal of medicine.

[29]  J. She,et al.  Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes , 2005, Journal of autoimmune diseases.

[30]  J. Madrenas,et al.  Hierarchical Regulation of CTLA-4 Dimer-Based Lattice Formation and Its Biological Relevance for T Cell Inactivation1 , 2005, The Journal of Immunology.

[31]  Graça Raposo,et al.  Exosomal-like vesicles are present in human blood plasma. , 2005, International immunology.

[32]  Y. Belkaid,et al.  Association of CTLA4 polymorphism with regulatory T cell frequency , 2005, European journal of immunology.

[33]  W. van Eden,et al.  Uptake of membrane molecules from T cells endows antigen‐presenting cells with novel functional properties , 2004, European journal of immunology.

[34]  M. Fujimoto,et al.  Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. , 2004, Rheumatology.

[35]  Rong-Fong Shen,et al.  Identification and proteomic profiling of exosomes in human urine. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Luc J. Smink,et al.  Fine Mapping, Gene Content, Comparative Sequencing, and Expression Analyses Support Ctla4 and Nramp1 as Candidates for Idd5.1 and Idd5.2 in the Nonobese Diabetic Mouse 1 , 2004, The Journal of Immunology.

[37]  G. Eisenbarth,et al.  Heterophile Antibodies Masquerade as Interferon-α in Subjects With New-Onset Type 1 Diabetes , 2004 .

[38]  L-L Fung,et al.  Increased Expression of Soluble Cytotoxic T‐Lymphocyte‐Associated Antigen‐4 Molecule in Patients with Systemic Lupus Erythematosus , 2003, Scandinavian journal of immunology.

[39]  Luc J. Smink,et al.  Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease , 2003, Nature.

[40]  U. Grohmann,et al.  CTLA-4–Ig regulates tryptophan catabolism in vivo , 2002, Nature Immunology.

[41]  Laurence Zitvogel,et al.  Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.

[42]  A. Régnault,et al.  TCR Activation of Human T Cells Induces the Production of Exosomes Bearing the TCR/CD3/ζ Complex1 , 2002, The Journal of Immunology.

[43]  P. Ricciardi-Castagnoli,et al.  Proteomic Analysis of Dendritic Cell-Derived Exosomes: A Secreted Subcellular Compartment Distinct from Apoptotic Vesicles1 , 2001, The Journal of Immunology.

[44]  T. Mak,et al.  Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4 , 2000, The Journal of experimental medicine.

[45]  M. Oaks,et al.  Cutting Edge: A Soluble Form of CTLA-4 in Patients with Autoimmune Thyroid Disease , 2000, The Journal of Immunology.

[46]  M. Oaks,et al.  A native soluble form of CTLA-4. , 2000, Cellular immunology.

[47]  J. Bonnefoy,et al.  A soluble form of CTLA‐4 generated by alternative splicing is expressed by nonstimulated human T cells , 1999, European journal of immunology.

[48]  M. Martínez-Lorenzo,et al.  Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. , 1999, Journal of immunology.

[49]  I. Kaplan,et al.  When is a heterophile antibody not a heterophile antibody? When it is an antibody against a specific immunogen. , 1999, Clinical chemistry.

[50]  G. Raposo,et al.  Accumulation of major histocompatibility complex class II molecules in mast cell secretory granules and their release upon degranulation. , 1997, Molecular biology of the cell.

[51]  P. Nickerson,et al.  CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. , 1997, Journal of immunology.

[52]  C. Melief,et al.  B lymphocytes secrete antigen-presenting vesicles , 1996, The Journal of experimental medicine.

[53]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[54]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[55]  P. Linsley,et al.  Binding Stoichiometry of the Cytotoxic T Lymphocyte-associated Molecule-4 (CTLA-4) , 1995, The Journal of Biological Chemistry.

[56]  R. Karr,et al.  Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. , 1995, The Journal of clinical investigation.

[57]  P. Linsley,et al.  Treatment of murine lupus with CTLA4Ig. , 1994, Science.

[58]  P. Linsley,et al.  CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.

[59]  J. Gribben,et al.  Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. , 1993, Science.

[60]  P. Linsley,et al.  Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion , 1993, The Journal of experimental medicine.

[61]  P. Linsley,et al.  Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. , 1992, Science.

[62]  P. Linsley,et al.  Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. , 1992, Science.

[63]  G. Freeman,et al.  B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. , 1989, Journal of immunology.

[64]  F. Denizot,et al.  A new member of the immunoglobulin superfamily—CTLA-4 , 1987, Nature.

[65]  J. Stockman.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial , 2010 .

[66]  Helen Schuilenburg,et al.  Genome-wide association study and meta-analysis finds over 40 loci affect risk of type 1 diabetes , 2009, Nature Genetics.

[67]  G. Eisenbarth,et al.  Heterophile antibodies masquerade as interferon-alpha in subjects with new-onset type 1 diabetes. , 2004, Diabetes care.

[68]  L. Boscato,et al.  Heterophilic antibodies: a problem for all immunoassays. , 1988, Clinical chemistry.

[69]  F. Powrie,et al.  Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation , 2000, Journal of Experimental Medicine.

[70]  Jane Worthington,et al.  Extended Report , 2022 .